Oltipraz

SKU: orb1310889

Description

Oltipraz

Research Area

Cardiovascular Research, Epigenetics & Chromatin, Immunology & Inflammation, Infectious Disease & Virology, Metabolism Research, Protein Biochemistry

Key Properties

• CAS Number: 64224-21-1
• MW: 226.34
• Purity: 98.79%
• Formula: C₈H₆N₂S₃
• SMILES: CC1=C(SSC1=S)C1=NC=CN=C1
• Target: HIV Protease,Nrf2,HIF,Parasite,Reverse Transcriptase,HIF/HIF Prolyl-Hydroxylase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (4.42 mM);DMSO:15.29 mg/mL (67.55 mM)

Bioactivity

• Target IC50:
  HIF1α:10 μM
• In Vivo:
  Oltipraz (500 mg/kg, p.o.) significantly reduces multiplicity of gastric neoplasia in wild-type mice by 55%, but has no effect on tumor burden in nrf2-deficient mice. In BALB/c nude mice transplanted with HCT116 cells, Oltipraz (200 mg/kg, p.o.) inhibits tumor growth and angiogenesis via inhibition of HIF-1α. In rats on a CDAA diet, Oltipraz attenuate the progression of nonalcoholic steatohepatitis-related fibrosis.
• In Vitro:
  Oltipraz, as a chemoprotective agent, induces Phase II detoxification enzyme activity in a Nrf2-dependent manner. In human HT29 colon cancer cells, oltipraz inhibits the induction of HIF-1α by insulin, hypoxia or CoCl2 by significantly accelerating degradation of HIF-1α protein.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Keap1-Nrf2, Inhibitor, NSC 347901, NSC347901, NSC-347901, Oltipraz, HIV Protease, HIV, HIVProtease, HIF, HIF/HIF ProlylHydroxylase, HIF Prolyl-Hydroxylase, HIF ProlylHydroxylase, HIF/HIF Prolyl-Hydroxylase, HIF/HIFProlylHydroxylase, HIFProlylHydroxylase, HIFs, HIF-1α, HIF-PH, Human immunodeficiency virus, Hypoxia-inducible factors, ReverseTranscriptase, Reverse Transcriptase, RP 35972, RP35972, RP-35972

Compound Identifiers

PubChem CID

47318